Decathlon Capital Partners invests in Amprion Inc
The investment will support the expansion of Amprion's diagnostic testing capacity for neurodegenerative diseases such as Parkinson's, Lewy body dementia, and Alzheimer's.
Takeaways
- Amprion is a diagnostics firm focused on neurodegenerative diseases.
- Decathlon Capital Partners is investing in Amprion.
- The business serves neurodegenerative disease diagnostics.
Decathlon Capital Partners has made a platform investment in Amprion Inc, a diagnostics company that develops and markets tests for neurodegenerative diseases.
The company's testing menu includes assays for Parkinson's disease, Lewy body dementia, and Alzheimer's disease, conditions that collectively affect millions of patients worldwide.
Proceeds from the investment will be deployed to increase Amprion's laboratory capacity, enhance its test offerings, and expand its clinical partnerships.
The transaction establishes a beachhead for Decathlon in the diagnostics space, aligning with the growing need for accurate neurodegenerative testing.
Get tomorrow morning's tape in your inbox.
Yesterday's platforms, add-ons, recaps, and exits, cleaned up before the workday starts.